89 results
424B5
WINT
Windtree Therapeutics, Inc.
3 Sep 24
Prospectus supplement for primary offering
9:10am
associated with the impact of the residual effects of the COVID-19 pandemic and the evolving events in Israel and Gaza on our clinical trial operations
424B5
WINT
Windtree Therapeutics, Inc.
3 Sep 24
Prospectus supplement for primary offering
9:09am
pandemic and the evolving events in Israel and Gaza on our clinical trial operations;
the costs, timing, and results, of our preclinical studies
8-K
EX-99.1
WINT
Windtree Therapeutics, Inc.
20 Aug 24
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
4:30pm
of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts
8-K
EX-99.1
t9r65g
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
8-K
EX-99.1
nac9m
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-99.1
55hixghsk el40w
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
khclazeu5g onqaaoif
9 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
nibvgm9j
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm